Mycenax Biotech Past Earnings Performance

Past criteria checks 0/6

Mycenax Biotech's earnings have been declining at an average annual rate of -41.5%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 8.1% per year.

Key information

-41.5%

Earnings growth rate

-29.6%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate8.1%
Return on equity-23.0%
Net Margin-88.7%
Next Earnings Update12 Nov 2024

Recent past performance updates

Recent updates

Mycenax Biotech's (GTSM:4726) Earnings Are Of Questionable Quality

Apr 05
Mycenax Biotech's (GTSM:4726) Earnings Are Of Questionable Quality

Update: Mycenax Biotech (GTSM:4726) Stock Gained 38% In The Last Year

Jan 07
Update: Mycenax Biotech (GTSM:4726) Stock Gained 38% In The Last Year

Revenue & Expenses Breakdown

How Mycenax Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4726 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24577-51212167
31 Mar 24594-57714867
31 Dec 23653-68315176
30 Sep 23666-713164106
30 Jun 23712-764218126
31 Mar 23645-713190139
31 Dec 22732-454187144
30 Sep 22757-327138126
30 Jun 22752-233149116
31 Mar 22708-186131103
31 Dec 21774-9012796
30 Sep 21732-4611177
30 Jun 217251910457
31 Mar 2188816711652
31 Dec 206653110547
30 Sep 20619197105
30 Jun 20548-7993184
31 Mar 20394-18884230
31 Dec 19391-21878285
30 Sep 19346-26872337
30 Jun 19327-23172301
31 Mar 19260-25661311
31 Dec 18211-27461276
30 Sep 18218-29664227
30 Jun 18285-21962216
31 Mar 18311-18665190
31 Dec 17319-18866195
30 Sep 17299-9659191
30 Jun 17260-14250214
31 Mar 17216-17145217
31 Dec 16201-15841218
30 Sep 16185-15336196
30 Jun 16155-13333170
31 Mar 16133-13435154
31 Dec 15135-11133145
30 Sep 15130-9133144
30 Jun 1584-12634143
31 Mar 15120-8029148
31 Dec 14113-8728149
30 Sep 1499-10030139
30 Jun 1497-9029131
31 Mar 1468-10030116
31 Dec 1364-8930103

Quality Earnings: 4726 is currently unprofitable.

Growing Profit Margin: 4726 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4726 is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.

Accelerating Growth: Unable to compare 4726's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4726 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (33.2%).


Return on Equity

High ROE: 4726 has a negative Return on Equity (-22.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies